The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis
Purpose: To explore the predictive efficacy of tumor mutation burden (TMB) as a potential biomarker for cancer patients treated with Immune checkpoint inhibitors (ICIs). Methods: We systematically searched PubMed, Cochrane Library, Embase and Web of Science for clinical studies (published between Ja...
Main Authors: | Jinlong Cao, Xin Yang, Siyu Chen, Jirong Wang, Xinpeng Fan, Shengjun Fu, Li Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-06-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523322000377 |
Similar Items
-
Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
by: Rui-Yan Wu, et al.
Published: (2023-01-01) -
Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
by: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et al.
Published: (2021-11-01) -
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
by: Camille Moeckel, et al.
Published: (2023-04-01) -
Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors
by: Camila B. Xavier, et al.
Published: (2022-11-01) -
BLM mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers
by: Huiping Shi, et al.
Published: (2024-01-01)